HII — Huntington Ingalls Industries, Inc.

As of 2026-08-27, the tape is mixed: strong Q2 earnings and revenue beat a raised outlook, but negative first-half free cash flow, a 14.7% deficit to the 200-day SMA, and a divided analyst consensus keep sentiment in check. RSI at 43.5 shows no momentum bid, but the $333–$334 average price target and 11 buy ratings prevent outright bearishness.

Revenue growth has been solid but slightly decelerating: +16.1% YoY in Q3'25, +15.7% in Q4'25, +13.3% in Q1'26, and +10.9% in Q2'26 to $3.42B. Q2'26 EPS jumped to $5.27 from $3.86 a year earlier, and operating margin widened to 6.1% from 4.5% in Q4'25, though it remains below the 9.8% peak in Q4'23. The real weak spot is cash conversion: H1'26 FCF was -$569M versus +$265M in H1'25, and the 1.88% positive accrual ratio flags earnings running ahead of cash. This is largely contract-timing, not collapsing demand, especially with a $57.3B backlog and an expected >$1B Q4 FCF inflection.

As of 2026-08-27, HII is fairly valued, not cheap. Trailing P/E is 17.7x versus its 5-year average of 16.1x; forward P/E on estimated EPS of $18.52 is about 16.0x, roughly in line with history. P/S of 0.89x is also near the 5-year average of 0.86x. The 0.69 PEG looks cheap only if you accept a high embedded long-term growth rate; against a conservative 10–11% forward EPS growth, the multiple is not a screaming bargain.

At $297.29 as of 2026-08-27, the market is paying about 16x forward earnings, which prices in competent execution but not major margin upside. Estimates are already moving up after the Q2 beat and guidance raise, so the stock is not discounting an earnings miss. If HII delivers the Q4 FCF explosion, the stock could re-rate toward the $333 analyst target; if cash conversion slips again, the low P/E becomes a value trap. This is a bet on the timing of cash, not on whether demand exists.

As of 2026-08-27, RSI was 43.5—neutral, not oversold. Price was 5.7% below the 20-day SMA, 0.3% above the 50-day SMA, and 14.7% below the 200-day SMA. That is a long downtrend trying to base, with no oversold capitulation and no bullish 50/200-day crossover. A sustained reclaim of the 50-day and RSI above 50 would improve entry timing; until then, the path of least resistance is sideways-to-down with support near $263.62.

• Indo-Pacific naval buildup and U.S. Navy fleet expansion underpin multi-decade carrier and submarine demand.
• Skilled-labor shortages and shipyard wage inflation pressure margins; labor cost pass-throughs boost revenue but squeeze operating leverage.
• Federal budget and appropriations risk: debt-ceiling fights or future defense cuts could delay program funding despite strategic tailwinds.
• Interest rates affect defense multiples and discount rates; higher rates pressure valuation even on defensive cash flows.
• Sole-source / duopoly positions on nuclear carriers and submarines create high barriers to entry and long-term pricing power.

• Q4 2026 free-cash-flow inflection: company expects >$1B in Q4 FCF and $500–600M for full-year 2026.
• Delivery and acceptance milestones for CVN-79 John F. Kennedy and continued Virginia-class / Columbia-class submarine progress.
• FY2027 defense appropriations and new long-lead shipbuilding funding.
• Q3/Q4 earnings prints confirming operating margins can hold at or above 6%.

• FCF and cash risk: cash and equivalents were just $12M at Q2'26; a slip in Q4 milestone payments would pressure the balance sheet and the stock.
• Thin margins and fixed-price contract risk: operating margin around 5.2% leaves little room for labor or supply-chain cost overruns.
• Budget and appropriations risk: any defense-spending reduction or government shutdown can delay shipbuilding schedules.
• Execution risk on the submarine ramp: Columbia and Virginia production-rate increases are steep, and schedule slips hit revenue and cash timing.

HII has genuine strategic moats, growing revenue, and a $57.3B backlog, but as of 2026-08-27 the stock is not yet a compelling buy at about 16x forward earnings with negative first-half FCF and no technical uptrend. The Q4 cash inflection is the pivotal catalyst: if it prints, shares likely re-rate toward the mid-$300s; if it misses, the low P/E is justified. Directionally, I lean bearish/neutral at this price—analysis, not personalized advice.

Applied a 17.0x forward P/E—a modest premium to HII's 5-year average of 16.1x, justified by the $57.3B backlog and expected double-digit EPS growth—to consensus forward EPS of $18.52, yielding $314.82. That is below the Street's $333 average target because weak 2026 cash generation and thin margins warrant a discount to analyst optimism.